<DOC>
	<DOCNO>NCT01368042</DOCNO>
	<brief_summary>The purpose study ass health-related Quality Life ( QoL ) change participant chronic kidney disease ( CKD ) secondary hyperparathyroidism ( sHPT ) undergo hemodialysis receive paricalcitol intravenous ( iv ) .</brief_summary>
	<brief_title>Quality Life Greek Hemodialysis Patients Receiving Zemplar Intravenous</brief_title>
	<detailed_description>The scientific purpose study obtain data use paricalcitol iv real-life clinical practice effect participant health-related QoL . In study , paricalcitol iv prescribe on-label basis everyday setting . The RAND 36-Item Health Survey result collect 6-month period ( every 3 month ) order assess effect paricalcitol iv participant health-related QoL .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>1 . Patients chronic kidney disease stage 5 undergoing hemodialysis receive paricalcitol iv 1 month . 2 . Patients RAND 36Item Health Survey complete 10 35 day paricalcitol iv initiation 3 . Patients baseline parathormone â‰¥ 300 pg/mL 4 . Patients willing give inform consent participate study . 5 . Patients receive vitamin Drelated compound cinacalcet 3 month prior enter study 6 . Patients must steady regimen anemia , hypertension diabetes past 30 day 1 . Patients history clinically significant intolerance sensitivity vitamin D ingredient product . 2 . Patients persistent hypercalcemia evidence vitamin D toxicity . 3 . Patients continuous increase serum ( calcium x phosphorus ) product great 65 . 4 . Pregnant lactate female patient . 5 . Patients previously undergone parathyroidectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Quality Life change</keyword>
	<keyword>Secondary Hyperparathyroidism</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Paricalcitol intravenous treatment</keyword>
</DOC>